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High long-term absolute risk of recurrent venous thromboembolism in patients with 
hereditary deficiencies of protein S, protein C or antithrombin
Jan Leendert P. Brouwer, Willem M. Lijfering, Hanneke C. Kluin-Nelemans, Nic 





Hereditary deficiencies of protein S, protein C and antithrombin are known risk fac-
tors for first venous thromboembolism. We assessed the absolute risk of recurrence, 
and the contribution of concomitant thrombophilic defects in a large cohort of fami-
lies with these deficiencies. Annual incidence of recurrence was estimated in 130 de-
ficient patients, with separate estimates for those with each of protein S, protein C, 
and antithrombin deficiency, and in eight non-deficient patients with prior venous 
thromboembolism. All patients were also tested for factor V Leiden, prothrombin 
G20210A, high levels of factors VIII, IX and XI, and hyperhomocysteinemia. There 
were 81 recurrent events among 130 deficient patients. Median follow-up was 4.6 years. 
Annual incidences (95% confidence interval) of recurrent venous thromboembolism 
were 8.4% (5.8-11.7) for protein S deficiency, 6.0% (3.9-8.7) for protein C deficiency, 
10.0% (6.1-15.4) for antithrombin deficiency, and overall 7.7% (6.1-9.5). Relative risk 
of recurrence in patients with a spontaneous versus provoked first event was 1.5 (0.95-
2.3). Cumulative recurrence rates at 1, 5 and 10 years were 15%, 38% and 53%. Relative 
risk of recurrence with concomitant defects was 1.4 (0.7-2.6) (1 defect) and 1.4 (0.8-2.7) 
(≥2 defects). Annual incidence was 1.0% (0.03-5.5) in eight non-deficient patients. An-
nual incidence of major bleeding in deficient patients on oral anticoagulant treatment 
was 0.5% (0.2-1.0). We conclude that patients with a hereditary protein S, protein C or 
antithrombin deficiency appear to have a high absolute risk of recurrence. This risk is 





Hereditary deficiencies of protein S, protein C and antithrombin are associated with 
a high risk of first venous thromboembolism (Vte) (1-3). Whether patients with one 
of these deficiencies should be treated with anticoagulants for a prolonged time after 
their first episode of Vte is still a matter of debate (4). This depends on the risk of 
recurrence, and the risk of major bleeding due to continued anticoagulant treatment. 
The risk of major bleeding in unselected patients on treatment with vitamin K an-
tagonists (VKA) is estimated to be 2-3% per year (5). Data on this risk in patients with 
hereditary anticoagulant deficiencies is not available. The risk in unselected patients 
cannot be extrapolated to deficient patients, considering that hypercoagulability as a 
result of thrombophilic defects may reduce the risk of bleeding. two recent prospective 
studies reported a similar risk of recurrence in patients with first Vte and a throm-
bophilic defect, compared to patients without a thrombophilic defect (6,7). However, 
these studies also included patients with factor V Leiden, prothrombin G20210A, high 
levels of factors VIII, IX and XI, hyperfibrinogenemia, or hyperhomocysteinemia. It 
is unlikely that the risk of recurrence for all these defects is comparable to the risk of 
recurrence associated with hereditary deficiencies of anticoagulants, considering the 
difference in risk of first Vte (8). 
 We performed a retrospective study in a large cohort of families with hereditary 
deficiencies of either protein S, protein C or antithrombin to assess the absolute risk 
of recurrence of Vte and the contribution of concomitant other thrombophilic de-




Subjects in the present single center retrospective study were all patients with he-
reditary deficiencies of either protein S, protein C or antithrombin from a previous 
large family cohort study (1), who already had experienced a first episode of Vte. 
In that study, subjects were enrolled between April 1999 and July 2004. Follow-up 
ended at date of enrolment. Probands were consecutive patients with Vte and with 
one of these deficiencies. First-degree relatives were identified by pedigree analysis. 
As the number of antithrombin deficient probands was small, second-degree relatives 
from a deficient parent were also included. After written informed consent was ob-
tained, detailed information was collected on previous episodes of Vte, exposures 
to exogenous risk factors, and in women the use of oral contraceptives and their ob-
stetric history. A standardized questionnaire was used (9), and medical records were 
reviewed. In addition to the index deficiency, all subjects were tested for concomitant 
thrombophilic defects. These included a second deficiency of either protein S, protein 
C or antithrombin, factor V Leiden, prothrombin G20210A, elevated plasma levels of 
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factors VIII:C, IX:C and XI:C, and hyperhomocysteinemia. A first episode of Vte was 
initially treated with (low-molecular-weight) heparin, followed by VKA for three to 
six months. Afterwards, thromboprophylaxis was recommended at exposure to exog-
enous risk factors, i.e. surgery, immobilization for more than seven days, pregnancy 
and six weeks after delivery. Oral contraceptives and hormonal replacement therapy 
were strongly discouraged after Vte had occurred. The study was approved by the 
institutional review board of our hospital.
Definitions
The first episode of Vte was considered established if proximal deep-vein thrombo-
sis (DVt) was confirmed by compression ultrasound or venography, and pulmonary 
embolism (Pe) by ventilation/perfusion lung scanning, helical computed tomography 
(Ct) scanning or pulmonary angiography, or when the patient had received full dose 
heparin and a VKA for at least three months without objective testing at a time when 
these techniques were not available yet. events were independently adjudicated and 
were classified with the following criteria: isolated calf-vein thrombosis and super-
ficial phlebitis were not classified as a thrombotic event. Recurrence was considered 
established if it was demonstrated by objective techniques at another site than the first 
event, or at the same site if previously repeated tests showed no residual Vte. If recur-
rence of DVt at the same site was suspected, but objective tests were not conclusive, 
it was diagnosed when the patient revealed pronounced signs and symptoms of re-
currence without preceding postthrombotic syndrome, or when Pe was objectively 
demonstrated. If these criteria were not fulfilled, anticoagulant treatment was omitted. 
Vte was considered secondary, if it had occurred at or within three months after 
exposure to one or more exogenous risk factors, including surgery, trauma, immobi-
lization for more than seven days, use of oral contraceptives, hormonal replacement 
therapy, pregnancy/puerperium, and current malignancy. In the absence of these risk 
factors, it was classified as spontaneous.
 Clinically overt bleedings, which required hospitalization or blood transfusion, 
were intracranial or retroperitoneal, or if they led directly to death were classified as 
major (10).
Laboratory studies
Protein S and protein C antigen levels were measured by enzym Linked Immuno 
Sorbent Assay (eLISA) (DAKO, Glostrup, Denmark), activity of protein C (Berichrom 
Protein C, Dade Behring, Liederbach, Germany) and antithrombin (Coatest, Chro-
mogenix, Mölndal, Sweden) by chromogenic substrate assays. Protein S deficiency 
type I was defined by decreased total protein S levels (<65 IU/dL), and protein S type 
III deficiency by decreased free protein S levels (< 65 IU/dL) and normal total protein 
S levels. After we had demonstrated that type III protein S deficiency was not a risk 
factor for thrombosis, families with this deficiency were excluded from analysis (11). 
Protein C deficiency type I and type II were defined by decreased levels of either pro-
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tein C antigen (< 65 IU/dL) and/or activity (< 65 IU/dL), antithrombin deficiency by 
decreased levels of antithrombin activity (< 70 IU/dL). Deficiencies were considered 
inherited if confirmed by measurement of a second sample collected at a three-month 
interval and demonstrated in at least two family members, while acquired conditions 
were excluded. Protein S deficiency was considered to be acquired, due to pregnancy 
or use of oral contraceptives, unless it was established by repeated measurement at 
least three months after delivery and discontinued use of oral contraceptives, respec-
tively. Factor V Leiden and prothrombin G20210A were demonstrated by polymer-
ase chain reactions (PCR) (12,13). Factors VIII:C, IX:C and XI:C were measured by 
one-stage clotting assays (Amelung GmbH, Lemgo, Germany) and were considered 
increased at levels above 150 IU/dL (14). Fasting and post-methionine-loading lev-
els of homocysteine were measured by high performance liquid chromatography (15). 
Hyperhomocysteinemia was defined as a fasting level above 18.5 μM and/or a post-
methionine-loading level above 58.8 μM, as described in the Dutch population (16,17). 
Because the study was retrospective and laboratory tests were performed at the end 
of the observation period, clinical outcome was not influenced by the results of these 
tests. 
 Blood samples were collected at least three months after Vte had occurred. If pa-
tients were on long-term treatment with VKA at time of enrolment, samples were tak-
en after treatment had been interrupted for at least two weeks, meanwhile nadroparin 
was given subcutaneously.
Statistical analysis
Probands and deficient relatives were pooled to estimate the absolute risk of a first 
recurrence for each of the three deficiencies separately and overall. Annual recurrence 
rates were calculated by dividing the number of relatives with a second episode of Vte 
by the total number of observation years. Observation time was defined as the period 
from the end of treatment with VKA for the first episode of Vte until the onset of 
the second episode or the end of follow-up. to assess the effects of concomitant other 
thrombophilic defects on the risk of recurrence, patients were categorized as to the 
number of concomitant defects. Accurate estimates for separate combinations could 
not be performed, because numbers in subgroups were too small. Relative risks and 
95% confidence intervals (CI) were used to compare absolute risks. Recurrence-free 
survival was estimated by the Kaplan-Meier method. 
 Continuous variables were expressed as median values and ranges and categorical 
data as counts and percentages. Differences between groups were evaluated by the 
Student t-test or Mann-Whitney U-test, depending on the normality of data for con-
tinuous data and by Fisher exact test for categorical data. A two-tailed P-value of less 
than 0.05 indicated statistical significance. All analyses were performed using SAS® for 




Ninety-one probands with deficiencies of either protein S (n=39), protein C (n=40) 
or antithrombin (n=12) were identified (Figure 1). Of their 725 relatives, 528 were alive 
and aged 15 years or older. Consent was not obtained from 41 relatives (7.8%). Seven 
probands (5 protein S deficient and 2 protein C deficient) and their relatives (15 and 
4, respectively) were excluded because inheritance of the index deficiency was not 
established by testing relatives. Of the remaining 468 relatives (224 deficient, 244 non-
deficient), 374 had a history of Vte (141 deficient, 233 non-deficient) and were not eli-
gible for the present study. Another 40 patients (13 probands, 24 deficient relatives, and 
3 non-deficient relatives) were excluded because they were on treatment with VKA, 
while this treatment could not be interrupted. All these patients were on long-term 
treatment since their first venous thromboembolic event. In two patients a previous 
ischemic stroke had occurred, three patients had had a mesenteric vein or cereberal 
sinus thrombosis, whereas 35 patients were on long-term treatment, as decided by the 
treating physician, although not strictly indicated. None of these patients had recur-
rent Vte. Only 11 of 244 non-deficient relatives had a first episode of Vte. Their first 
thromboembolic event was provoked by major trauma or surgery (n=7), pregnancy 
(n=2), or oral contraceptive use (n=1), and was idiopathic in only one patient. Three 
Figure 1. Recruitment of three family cohorts with hereditary deficiencies of either 
protein S, protein C or antithrombin.
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non-deficient patients had no follow-up, as they were on long-term oral anticoagulant 
treatment. Of the remaining 138 subjects, 130 were deficient for either protein S (n=53), 
protein C (n=52) or antithrombin (n=25), and eight were non-deficient. The number 
of non-deficient patients with a first episode of Vte was too small to enable a proper 
comparison with deficient patients. 
 Characteristics of probands and deficient relatives are summarized in table 1. Rela-
tive risk of recurrent Vte in probands compared to relatives was 1.3 (95% CI, 0.8-2.0). 
Because no statistical differences were found, both groups were pooled. Median ages 
at onset of the first thrombotic event and recurrence were 29 years and 37 years, re-
spectively. DVt was the most frequently recorded event; 69% of first events and 84% 
of recurrences. Of first events, 39% were classified spontaneous, compared to 64% of 
recurrences. Most recurrences (74%) occurred at another site than the first event. Me-
dian follow-up after the end of anticoagulant treatment was 4.6 years. Concomitant 
thrombophilic defects were observed in 72% of all patients. These defects exceeded 
the prevalences as reported in the normal population excepted for increased factor IX 
levels (i.e., factor V Leiden, 5%; prothrombin G20210A, 3%; increased levels of factors 
VIII, IX and XI, each 10%; and hyperhomocysteinemia, 10%) (18). 
 Annual incidences of first recurrence were 8.4% (95% CI, 5.8-11.7) in protein S-de-
ficient patients, 6.0% (95% CI, 3.9-8.7) in protein C-deficient patients, 10.0% (95% CI, 
6.1-15.4) in antithrombin-deficient patients, and overall 7.7% (95% CI, 6.1-9.5) (table 2). 
Of eight non-deficient patients, one had recurrent Vte; annual incidence 1.0% (95% 
CI, 0.03-5.5). Annual incidence of first recurrence in patients with a spontaneous first 
event was 9.7% (6.8-13.4) and 6.6% (95% CI, 4.8-8.8) in patients with a secondary first 
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event; relative risk 1.5 (95% CI, 0.95-2.3) (table 3). 
 Men tended to be at higher risk of recurrence than women (relative risk 1.4; 95% 
CI, 0.9-2.2). Median age at onset of first Vte in men was 36 years (range, 15-68), and 
in women 26 years (range, 15-67) (P<0.001). Median recurrence free survival was five 
years in men compared to 12 years in women (Figure 2). Lifetime risk of recurrence in 
men and women was approximately 85%. 
 The risk of recurrence was not significantly increased by concomitance of other 
thrombophilic defects (table 4). Annual incidences were 6.0% (95% CI, 3.3-9.8) in 
deficient patients without concomitant defects, 8.0% (95% CI, 5.4-11.5) in the presence 
of one concomitant defect and 8.3% (95% CI, 5.6-11.8) in the presence of two or more 
concomitant defects. Cumulative recurrence rates at 1, 5 and 10 years follow-up were 
14%, 32% and 50%, respectively, in patients without concomitant thrombophilic de-
fects versus 14%, 40% and 54%, respectively, in patients with one or more concomitant 
defects.
 Major bleeding was observed in eight of 167 deficient patients while they were 
treated with VKA at median follow-up of 6.2 years (range, 0.6-34); annual incidence 




In this study, the annual incidence of first recurrence of Vte was 7.8%, with a median 
follow-up of 4.6 years, while cumulative recurrence rates were 42% at 5 years and 53% 
at 10 years follow-up. In a study obtained in the general population, the annual risk of 
recurrence was 3%, with a median follow-up of 7.4 years in patients with DVt and 6.1 
years in patients with Pe, and cumulative recurrence rates of Vte amounted to 22% 
at five years and 30% at 10 years (19). Hence, our patients were at high risk of recur-
rence. This risk was highest in deficient patients with a spontaneous first event. They 
had an annual recurrence risk of almost 10%, which was 1.5 times higher compared to 
patients with a secondary first event (P=0.08). The risk of recurrence in our study was 
higher than in two previous studies, which reported annual incidences of 4.8% and 
2.7%, respectively (20, 21). This incongruity may be due to differences in methodology 
between the studies. We applied strict criteria for deficiencies and excluded familial 
protein S deficiency type III from analysis because it was not identified as a risk factor 
for thrombosis (11). Moreover, we enrolled 92% of relatives, hereby avoiding selection 
bias.
 Aggregation of other thrombophilic defects in the here presented families does 
support the assumed multicausal pathogenesis of Vte (18). It increased the risk of re-
currence 1.4-fold, compared to patients without concomittant thrombophilic defects. 
 Men had a 1.4-fold higher risk of recurrent Vte compared to women. This seems 
in agreement with a previous meta-analysis that showed a 1.6-fold higher risk of recur-
rence in men (22). However, lifetime risk in men and women was comparable. Possi-
bly, follow-up was too short (maximum 8 years) in studies that suggested an increased 
risk of recurrence in men compared to women (7, 23). In our study, median recurrence 
free survival was 12 years in women and five years in men.
 The duration of anticoagulant treatment after a first episode of Vte not only de-
pends on the risk of recurrence, but also on the risk of haemorrhagic complications 
due to treatment. The risk of major bleeding in our study (0.5% per year in patients on 
100
chapter 6
VKA) was lower than previously reported in unselected patients with Vte, while they 
were treated with VKA (2-3% per year) (5,27). Recently, we reported on this risk in all 
patients who received VKA for treatment of Vte in our region. It amounted to 2.8% 
per year (24). Maybe, thrombophilic defects protect against major bleeding during 
anticoagulant treatment. However, the lower risk may also be due to the younger age 
of thrombophilic patients at time of their first thrombotic event. Nevertheless, the low 
risk of major bleeding will diminish the reluctance to extend anticoagulant treatment, 
considering the high risk of recurrent Vte after stopping treatment and the low risk 
of bleeding during treatment. A possible implication of our findings may be longterm 
anticoagulant treatment after a first episode of Vte.
 Some aspects of our retrospective study need comment. First, it is often difficult 
to establish recurrence of Vte at the same site as the first event, even with objec-
tive techniques. Furthermore, patients with clinical suspicion of Vte and who were 
treated with heparin and VKA for more than three months at a time when there was 
no objective testing yet, might have overestimated our recurrence rates of thrombosis. 
However, most recurrences were demonstrated at another site than the first event. 
Second, the number of non-deficient relatives who had experienced a first episode of 
Vte was too small to be used as a proper reference group. Therefore, we compared 
our recurrence rates with population studies that classified recurrent Vte in the same 
way as we did (19-21). Still, our results should be handled with caution, because of 
the lack of a proper control group. Third, as death causes were not investigated in de-
tail, an excess of fatal Pe in relatives with a deficiency might have underestimated the 
risk of recurrence. However, these deficiencies were not associated with a reduced life 
expectancy in previous studies (25,26). Finally, although our study comprised a rela-
tively small number, it has the longest follow-up period and is the largest till date on 
recurrent Vte in patients with hereditary anticoagulant deficiencies. Of two studies 
that suggested that thrombophilic defects did not influence the risk of recurrence, one 
study had a limited follow-up period of two years (6), while the other study contained 
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a small number of patients with deficiencies of antithrombin, protein C or protein S 
(overall number 25, including patients on VKA at time of blood collection, in whom 
classification of protein C and protein S might consequently be inaccurate) (7).
 Strong points of our study are that probands were identified by testing consecutive 
patients with first Vte; secondly, the study cohort contained 92% of living relatives 
aged 15 years and older; thirdly, all patients were tested for currently known throm-
bophilic defects; and finally, its design as a family cohort study enabled us to estimate 
absolute risks.
 In conclusion, patients with hereditary deficiencies of protein S, protein C or anti-
thrombin appear to have a high absolute risk of recurrence. This risk is increased after 
a first spontaneous event, and by concomitance of other thrombophilic defects.
Figure 2. Recurrence free survival in men and women after a first episode of venous 
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